Expression of thioredoxin during progression of hamster and human cholangiocarcinoma

Cancer Science

Volumn 101, Issue 1, 2010, Pages 281-288

  Yoon, Byung Il ^a,b   Kim, Yeong Hun ^a   Yi, Jung Yeon ^a   Kang, Min Soo ^c   Jang, Ja June ^d   Joo, Kyoung Hwan ^e   Kim, Yongbaek ^b   McHugh Law, J ^b   Kim, Dae Yong ^c  

^a Kangwon National University   (South Korea)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c Seoul National University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOPLASM; GENE OVEREXPRESSION; HAMSTER; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; WESTERN BLOTTING;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; CHOLANGIOCARCINOMA; CRICETINAE; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MESOCRICETUS; PRECANCEROUS CONDITIONS; THIOREDOXINS;

EID: 71849098078     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01353.x     Document Type: Article

References (36)

1. Sirica AE, Lai GH, Endo K, Zhang Z, Yoon BI. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 2002, 22:303-13.
2. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41:5-15.
3. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005, 366:1303-14.
4. Pinlaor S, Hiraku Y, Ma N. Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini: a model of inflammation-mediated carcinogenesis. Nitric Oxide 2004, 11:175-83.
5. Laurent TC, Moore EC, Reichard P. Enzymatic synthesis of deoxyribonucleotides. VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli. B J Biol Chem 1964, 239:3436-44.
6. Wakasugi H, Rimsky L, Mahe Y. Epstein-Barr virus-containing B-cell line produces an interleukin 1 that uses as a growth factor. Proc Natl Acad Sci U S A 1987, 84:804-8.
7. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000, 29:312-22.
8. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001, 30:421-55.
9. Iwata S, Hori T, Sato N. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J Immunol 1997, 158:3108-17.
10. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005, 97:967-74.
11. Matsutani Y, Yamauchi A, Takahashi R. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 2001, 7:3430-6.
12. Noda N, Ochiai A, Miyazaki K, Sugimura T, Terada M, Wakasugi H. Detection of thioredoxin in gastric cancer: association with histological type. Antioxid Redox Signal 2000, 2:519-28.
13. Raffel J, Bhattacharyya AK, Gallegos A. Increased expression of thioredoxin-1 in human colorectal cancers is associated with decreased patient survival. J Lab Clin Med 2003, 142:46-51.
14. Soini Y, Kahlos K, Näpänkangas U. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 2001, 7:1750-7.
15. Kahlos K, Soini Y, Saily M. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 2001, 95:198-204.
16. Lee JH, Rim HJ, Sell S. Heterogeneity of the " oval-cell" response in the hamster liver during cholangiocarcinogenesis following Clonorchis sinensis infection and dimethylnitrosamine treatment. J Hepatol 1997, 26:1313-23.
17. Yoon BI, Kim YB. Overexpression of c-Fos in the dysplastic bile ducts and cholangiocarcinoma and its association with cell proliferating activity in the hamster cholangiocarcinoma model. Lab Anim Res 2008, 25:41-6.
18. Shimonishi T, Sasaki M, Nakanuma Y. Precancerous lesions of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2000, 7:542-50.
19. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002, 36:439-50.
20. Grogan TM, Fenoglio-Prieser C, Zeheb R. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000, 31:475-81.
21. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 2006, 387:365-72.
22. Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V. Inflammatory cytokines suppess NAD(P)H:quinine oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol 2009, 135:515-22.
23. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160:1-40.
24. Turunen N, Karihtala P, Mantyniemi A. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. APMIS 2004, 112:123-32.
25. Freemerman AJ, Gallegos A, Powis G. Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res 1999, 59:4090-4.
26. Bamberger AM, Milde-Langosch K, Rössing E, Goemann C, Löning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J Cancer Res Clin Oncol 2001, 127:545-50.
27. Holt JT, Gopal TV, Moulton AD, Nienhuis AW. Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. Proc Natl Acad Sci U S A 1986, 83:4794-8.
28. Nishikura K, Murray JM. Antisense RNA of proto-oncogene c-fos blocks renewed growth of quiescent 3T3 cells. Mol Cell Biol 1987, 7:639-49.
29. Sunters A, Thomas DP, Yeudall WA, Grigoriadis AE. Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity. J Biol Chem 2004, 279:9882-91.
30. Khan SA, Thomas HC, Toledano MB. p53 mutations in human cholangiocarcinoma: a review. Liver Int 2005, 25:704-16.
31. Tangkawattana S, Kaewkes S, Pairojkul C, Tangkawattana P, Sripa B. Mutations of KRAS and TP53 in a minor proportion of Opisthorchis viverrini-associated cholangiocarcinomas in a hamster model. Asian Pac J Cancer Prev 2008, 9:101-6.
32. Sirica AE, Nathanson MH, Gores GJ, LaRusso NF. Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton basic research single-topic conference. Hepatol 2008, 48:2040-6.
33. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002, 62:5089-95.
34. Li Y, Lu Z, Chen F. Antisense Bcl-2 transfection up-regulates anti-apoptotic and anti-oxidant thioredoxin in neuroblastoma cells. J Neurooncol 2005, 72:17-23.
35. Csiki I, Yanagisawa K, Haruki N. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1α in non-small cell lung cancer. Cancer Res 2006, 66:143-50.
36. Hadj Amor IY, Smaoui K, Chaabène I. Human p53 induces cell death and downregulates thioredoxin expression in Saccharomyces cerevisiae. FEMS Yeast Res 2008, 8:1254-62.